Clinical Trial Detail

NCT ID NCT01997333
Title Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Celldex Therapeutics
Indications

triple-receptor negative breast cancer

Therapies

Glembatumumab vedotin

Capecitabine

Age Groups: adult

Additional content available in CKB BOOST